Expression profile and biological function of miR‑455‑5p in colorectal carcinoma

Wang,Jinqiu; Lu,Yang; Zeng,Yiyong; Zhang,Leming; Ke,Kongliang; Guo,Yu

doi:10.3892/ol.2018.9862

Expression profile and biological function of miR‑455‑5p in colorectal carcinoma

Authors:
- Jinqiu Wang
- Yang Lu
- Yiyong Zeng
- Leming Zhang
- Kongliang Ke
- Yu Guo
View Affiliations

Affiliations: Department of Breast Surgery, Ningbo First Hospital, Ningbo, Zhejiang 315010, P.R. China, Medical School of Ningbo University, Ningbo, Zhejiang 315211, P.R. China, Department of Proctology, Ningbo First Hospital, Ningbo, Zhejiang 315010, P.R. China
Published online on: December 21, 2018 https://doi.org/10.3892/ol.2018.9862
Pages: 2131-2140
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Underexpression of microRNA‑455‑5p (miR‑455‑5p) in medullary thyroid carcinoma, melanoma, gastric cancer and additional cancer types has been reported, which may be associated with carcinoma development. The present study aimed to evaluate the expression profile and biological role of miR‑455‑5p in colorectal carcinoma. Carcinoma tissues and adjacent tissue specimens from 40 patients with colorectal cancer were randomly collected. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) analysis was conducted to detect the expression levels of miR‑455‑5p in colorectal carcinoma and adjacent normal tissues. The biological effects of miR‑455‑5p on selected colorectal cancer cells were assessed using bromodeoxyuridine assays, wound healing migration assays and flow cytometry. Bioinformatics analysis was implemented to predict the potential target genes of miR‑455‑5p in colorectal cancer. The expression levels of target genes were further validated by RT‑qPCR and western blot analysis of the mRNA and protein levels. The results of the experiments demonstrated that miR‑455‑5p expression was downregulated in colorectal cancer tissues compared with adjacent normal tissues. In colorectal cancer cells (SW‑480, HT‑29 and HCT‑116), miR‑455‑5p was observed to inhibit cell proliferation and migration while promoting cell apoptosis. Bioinformatics analysis predicted that the oncogene phosphoinositide‑3‑kinase regulatory subunit 1 (PIK3R1) was one of the top ranked target genes of miR‑455‑5p in colorectal cancer cells. This association was validated by RT‑qPCR and western blotting. In vivo studies revealed that the expression level of miR‑455‑5p was significantly downregulated in human colorectal cancer. Further in vitro studies suggested that miR‑455‑5p may prevent the development of colorectal cancer by downregulating the oncogene PIK3R1. It was concluded that miR‑455‑5p may target and downregulate PIK3R1 in colorectal cancer.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Zhang Y, Shi J, Huang H, Ren J, Li N and Dai M: Burden of colorectal cancer in China. Zhonghua Liu Xing Bing Xue Za Zhi. 36:709–714. 2015.(In Chinese). PubMed/NCBI
3	Brenner H, Stock C and Hoffmeister M: Colorectal cancer screening: The time to act is now. BMC Med. 13:2622015. View Article : Google Scholar : PubMed/NCBI
4	Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
5	Zoni E, van der Pluijm G, Gray PC and Kruithof-de Julio M: Epithelial plasticity in cancer: Unmasking a microRNA network for TGF-beta-, notch-, and Wnt-mediated EMT. J Oncol. 2015:1989672015. View Article : Google Scholar : PubMed/NCBI
6	Kohlhapp FJ, Mitra AK, Lengyel E and Peter ME: MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene. 34:5857–5868. 2015. View Article : Google Scholar : PubMed/NCBI
7	Yi R, Li Y, Wang FL, Miao G, Qi RM and Zhao YY: MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer. World J Gastrointest Oncol. 8:330–340. 2016. View Article : Google Scholar : PubMed/NCBI
8	Hudson J, Duncavage E, Tamburrino A, Salerno P, Xi L, Raffeld M, Moley J and Chernock RD: Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma. Exp Mol Pathol. 95:62–67. 2013. View Article : Google Scholar : PubMed/NCBI
9	Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, et al: Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol. 17:311–321. 2015. View Article : Google Scholar : PubMed/NCBI
10	Liu J, Zhang J, Li Y, Wang L, Sui B and Dai D: MiR-455-5p acts as a novel tumor suppressor in gastric cancer by down-regulating RAB18. Gene. 592:308–315. 2016. View Article : Google Scholar : PubMed/NCBI
11	Hari DM, Leung AM, Lee JH, Sim MS, Vuong B, Chiu CG and Bilchik AJ: AJCC Cancer Staging Manual 7th edition criteria for colon cancer: Do the complex modifications improve prognostic assessment? J Am Coll Surg. 217:181–190. 2013. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Liu S, Xie F, Wang H, Liu Z, Liu X, Sun L and Niu Z: Ubenimex inhibits cell proliferation, migration and invasion in renal cell carcinoma: The effect is autophagy-associated. Oncol Rep. 33:1372–1380. 2015. View Article : Google Scholar : PubMed/NCBI
14	Hirano S: Western blot analysis. Methods Mol Biol. 926:87–97. 2014. View Article : Google Scholar
15	Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, Li K, Yu B, Li Z, Wang R, et al: Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun. 391:73–77. 2010. View Article : Google Scholar : PubMed/NCBI
16	Cao J, Cai J, Huang D, Han Q, Yang Q, Li T, Ding H and Wang Z: miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. Oncol Rep. 30:701–706. 2013. View Article : Google Scholar : PubMed/NCBI
17	Niwa R and Slack FJ: The evolution of animal microRNA function. Curr Opin Genet Dev. 17:145–150. 2007. View Article : Google Scholar : PubMed/NCBI
18	Wightman B, Ha I and Ruvkun G: Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 75:855–862. 1993. View Article : Google Scholar : PubMed/NCBI
19	Feinbaum R and Ambros V: The timing of lin-4 RNA accumulation controls the timing of postembryonic developmental events in Caenorhabditis elegans. Dev Biol. 210:87–95. 1999. View Article : Google Scholar : PubMed/NCBI
20	Moss EG, Lee RC and Ambros V: The cold shock domain protein LIN-28 controls developmental timing in C. elegans and is regulated by the lin-4 RNA. Cell. 88:637–646. 1997. View Article : Google Scholar : PubMed/NCBI
21	Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
22	Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van Dongen S, Grocock RJ, Das PP, Miska EA, et al: Requirement of bic/microRNA-155 for normal immune function. Science. 316:608–611. 2007. View Article : Google Scholar : PubMed/NCBI
23	Sand M, Skrygan M, Sand D, Georgas D, Hahn SA, Gambichler T, Altmeyer P and Bechara FG: Expression of microRNAs in basal cell carcinoma. Br J Dermatol. 167:847–855. 2012. View Article : Google Scholar : PubMed/NCBI
24	Hummel R, Wang T, Watson DI, Michael MZ, Van der Hoek M Haier J and Hussey DJ: Chemotherapy-induced modification of microRNA expression in esophageal cancer. Oncol Rep. 26:1011–1017. 2011.PubMed/NCBI
25	Bellissimo T, Russo E, Ganci F, Vico C, Sacconi A, Longo F, Vitolo D, Anile M, Disio D, Marino M, et al: Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors. Cancer Biol Ther. 17:79–82. 2016. View Article : Google Scholar : PubMed/NCBI
26	Yang Q, Hou C, Huang D, Zhuang C, Jiang W, Geng Z, Wang X and Hu L: miR-455-5p functions as a potential oncogene by targeting galectin-9 in colon cancer. Oncol Lett. 13:1958–1964. 2017. View Article : Google Scholar : PubMed/NCBI
27	Peeters M and Price T: Biologic therapies in the metastatic colorectal cancer treatment continuum-applying current evidence to clinical practice. Cancer Treat Rev. 38:397–406. 2012. View Article : Google Scholar : PubMed/NCBI
28	Morillas JD, Castells A, Oriol I, Pastor A, Pérez-Segura P, Echevarría JM, Caballero B, González-Navarro A, Bandrés F, Brullet E, et al: The Alliance for the prevention of colorectal cancer in Spain. A civil commitment to society. Gastroenterol Hepatol. 35:109–128. 2012.(In Spanish).
29	He K, Jin K, Wang H and Teng L: Anti-angiogenic therapy for colorectal cancer: On the way to getting better! Hepatogastroenterology. 59:1113–1117. 2012.PubMed/NCBI
30	Ng F, Ganeshan B, Kozarski R, Miles KA and Goh V: Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: Contrast-enhanced CT texture as a biomarker of 5-year survival. Radiology. 266:177–184. 2013. View Article : Google Scholar : PubMed/NCBI
31	Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F and Morgillo F: Beyond bevacizumab: New anti-VEGF strategies in colorectal cancer. Expert opin Investig Drugs. 21:949–959. 2012. View Article : Google Scholar : PubMed/NCBI
32	Cizkova M, Vacher S, Meseure D, Trassard M, Susini A, Mlcuchova D, Callens C, Rouleau E, Spyratos F, Lidereau R and Bièche I: PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer. 13:5452013. View Article : Google Scholar : PubMed/NCBI
33	Lee SR, Kim SJ, Park Y, Sung HJ, Choi CW and Kim BS: Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. Korean J Hema. 45:183–187. 2010. View Article : Google Scholar
34	Franke TF: PI3K/Akt: Getting it right matters. Oncogene. 27:6473–6488. 2008. View Article : Google Scholar : PubMed/NCBI
35	Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, et al: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 64:280–285. 1995. View Article : Google Scholar : PubMed/NCBI
36	Xie J, Chen Y, Meng F, Shu T, Liu Y, Zhang L and Zhang ZX: Study on the relationship between the RASSF10 gene and the biological behavior of hepatocellular carcinoma cells. Eur Rev Med Pharmacol Sci. 21:3576–3580. 2017.PubMed/NCBI
37	Huang XP, Hou J, Shen XY, Huang CY, Zhang XH, Xie YA and Luo XL: MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1. FEBS J. 282:579–594. 2015. View Article : Google Scholar : PubMed/NCBI
38	Kaur J and Sanyal SN: PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: Chemoprevention by diclofenac. Tumour Biol. 31:623–631. 2010. View Article : Google Scholar : PubMed/NCBI